Hand-foot Syndrome Secondary to Low-dose Docetaxel in a Breast Cancer Patient

Tariq Kewan, Mohammad Alomari, Shrouq Khazaaleh, Fahrettin Covut, May Olayan, Tariq Kewan, Mohammad Alomari, Shrouq Khazaaleh, Fahrettin Covut, May Olayan

Abstract

Docetaxel-induced hand-foot syndrome (HFS) at low doses is a very rare side effect that usually occurs in a dose-dependent manner. HFS can be managed with conservative measures and may need chemotherapy discontinuation. In this report we present a case of HFS in a breast cancer patient after one dose of docetaxel.

Keywords: docetaxel; hand-foot syndrome.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Dorsal and plantar view of…
Figure 1. Dorsal and plantar view of both hands showing erythema and swelling bilaterally.

References

    1. Tunio MA, AlAsiri M, Durrani SK. Int J Health Sci (Qassim) Vol. 9. Int J Health Sci (Qassim). ; 2015. Hand foot syndrome secondary to low dose docetaxel; pp. 335–337.
    1. Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Am J Clin Oncol. Vol. 25. Am J Clin Oncol; 2002. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer; pp. 599–602.
    1. Harris CS, Wang D, Carulli A. J Oncol Pharm Pract. Vol. 20. J Oncol Pharm Pract; 2014. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature; pp. 73–80.
    1. Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA. Int J Health Sci (Qassim) Vol. 9. Int J Health Sci (Qassim); 2015. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia; pp. 335–337.
    1. Capecitabine and hand-foot syndrome. Saif MW. Expert Opin Drug Saf. 2011;10:159–169.
    1. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Piedbois P, Rougier P, Buyse M, et al. J Clin Oncol. 1998;16:301–308.
    1. Reduced cardiotoxicity and comparableefficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. O’Brien ME, Wigler N, Inbar M, et al. . Ann Oncol. 2004;15:440–449.
    1. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Scheithauer W, Blum J. Oncology (Williston Park) 2004 ;8:1161–1168.
    1. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Ho MY, Mackey JR. Cancer Manag Res. 2014;6:253–259.
    1. Novel & effective management of capecitabine induced hand foot syndrome. Yamamoto D, Yamamoto C, Tanaka K. J Clin Oncol. 2004;22:3099–3103.
    1. Docetaxel-induced hand foot syndrome: "No dose is a safe dose". Jain A, Dubashi B. . J Pharmacol Pharmacother. 2012;3:200–201.
    1. Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma. Gurumurthi R, Nimmagadda RB, Mohan S. Indian J Dermatol. 2013;58:380–382.
    1. Hand-foot syndrome after treatment with docetaxel. Sivaramamoorthy C, Thientosapol ES, Tattersall MH. Med J Aust. 2009;6:191.
    1. Management of paclitaxel-induced hand-foot syndrome. Assi HA, Ayoub ZA, Jaber SM, Sibai HA, El Saghir NS. Breast Care (Basel) 2013;8:215–217.
    1. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Gynecol Oncol. 2004;94:320–324.
    1. Pyridoxine for prevention of handfoot syndrome caused by chemotherapy: a systematic review. Chen M, Zhand L, Wang Q, Shen J. PLOS One. 2013;8:72245.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe